Oberdhan Dorothee, Bacci Elizabeth, Hill Jennifer N, Palsgrove Andrew, Hareendran Asha
Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.
Evidera, Seattle, WA, USA.
Neuropsychiatr Dis Treat. 2022 Mar 22;18:611-631. doi: 10.2147/NDT.S354031. eCollection 2022.
To identify concepts important to understanding the experiences of adults with focal onset seizures (FOS) and evaluate clinical outcome assessments (COAs) for measuring these concepts in clinical trials of treatments for FOS.
A search of published qualitative research, clinical trials, and approved product labels for FOS treatments was performed to develop a conceptual disease model (CDM) of patients' experience of living with FOS. Concepts of interest (COI) were selected, and a second literature search was conducted to identify COAs measuring these concepts. Ten COAs were selected and reviewed to document their development process, evidence of measurement properties, and methods for interpreting change scores using criteria proposed in regulatory guidelines for patient-reported outcomes to support label claims.
Concepts identified from the published literature (13 articles, 1 conference abstract), 24 clinical trials, and 8 product labels were included in a novel CDM. Impacts on physical, cognitive, and social and emotional function were chosen as COI for evaluating treatment outcomes for FOS; the additional concept of social support and coping strategies was chosen to understand patients' lived experiences. From 51 unique COAs identified, 10 were selected based on their potential coverage of the COI; some symptom severity and health-related quality of life (HRQoL) COAs covered multiple COI. Of these 10, 8 COAs evaluated impacts/limitations on physical function, 8 measured social and emotional impacts, and 5 assessed social support and coping strategies. While most assessments had gaps in evidence validating their measurement properties, 2 COAs measuring symptom severity and 1 COA measuring HRQoL had evidence confirming their potential utility in clinical trials to support label claims.
This research provides insights into the experience of patients with FOS and identifies COAs that measure concepts considered to support endpoints in clinical trials for FOS.
确定对于理解局灶性发作(FOS)成人患者经历至关重要的概念,并评估在FOS治疗临床试验中用于衡量这些概念的临床结局评估(COA)。
检索已发表的定性研究、临床试验以及FOS治疗的批准产品标签,以建立患者FOS生活经历的概念性疾病模型(CDM)。选择感兴趣的概念(COI),并进行第二次文献检索以识别衡量这些概念的COA。选择并审查了10个COA,以记录其开发过程、测量属性的证据以及使用患者报告结局监管指南中提出的标准解释变化分数以支持标签声明的方法。
从已发表的文献(13篇文章、1篇会议摘要)、24项临床试验和8个产品标签中确定的概念被纳入一个新的CDM。对身体、认知、社会和情感功能的影响被选为评估FOS治疗结局的COI;选择社会支持和应对策略这一额外概念以了解患者的生活经历。从确定的51个独特COA中,基于其对COI的潜在覆盖范围选择了10个;一些症状严重程度和健康相关生活质量(HRQoL)COA涵盖了多个COI。在这10个COA中,8个评估了对身体功能的影响/限制,8个测量了社会和情感影响,5个评估了社会支持和应对策略。虽然大多数评估在验证其测量属性的证据方面存在差距,但2个测量症状严重程度的COA和1个测量HRQoL的COA有证据证实它们在临床试验中支持标签声明的潜在效用。
本研究深入了解了FOS患者的经历,并确定了在FOS临床试验中衡量被认为支持终点的概念的COA。